Shopping Cart 0
Cart Subtotal
USD 0

EpiCast Report: Hemophilia-Epidemiology Forecast to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

EpiCast Report: Hemophilia-Epidemiology Forecast to 2026

Summary

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A, or factor IX (FIX) in hemophilia B. Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease.

In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.

GlobalData's epidemiologists forecast the epidemiological trend for hemophilia using the World Federation of Hemophilia (WFH) Annual Global Survey Report, which is considered the gold standard for hemophilia data. The World Health Organization (WHO) authenticates the WFH data for hemophilia and other bleeding disorders, and provides the most accurate data possible for hemophilia globally. The WFH Global Survey Report uses uniform data collection methods for each national member organization, allowing for a meaningful comparison of the diagnosed prevalent cases across the markets. A major strength of this analysis lays in the use of country-specific data and a uniform methodology across the markets to forecast the prevalent cases of hemophilia.

Scope

The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets.

The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to

Develop business strategies by understanding the trends shaping and driving the global hemophilia market.

Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.

Identify the percentage of hemophilia prevalent cases by type.

READ MORE

Table Of Content

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Hemophilia: Executive Summary 5

2.1 Related Reports 6

2.2 Upcoming Reports 6

3 Epidemiology 7

3.1 Disease Background 7

3.2 Risk Factors and Comorbidities 8

3.3 Global and Historical Trends 8

3.4 Forecast Methodology 10

3.4.1 Sources 10

3.4.2 Forecast Assumptions and Methods 13

3.4.3 Diagnosed Prevalent Cases 14

3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 15

3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors 18

3.5 Epidemiological Forecast for Hemophilia A (2016-2026) 19

3.5.1 Diagnosed Prevalent Cases of Hemophilia A 19

3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A 19

3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A 20

3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity 21

3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors 22

3.6 Epidemiological Forecast for Hemophilia B (2016-2026) 23

3.6.1 Diagnosed Prevalent Cases of Hemophilia B 23

3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B 23

3.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B 24

3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity 25

3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors 27

3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016-2026) 27

3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 27

3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 28

3.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 29

3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 30

3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 31

3.8 Discussion 32

3.8.1 Epidemiological Forecast Insight 32

3.8.2 Limitations of the Analysis 33

3.8.3 Strengths of the Analysis 33

4 Appendix 35

4.1 Bibliography 35

4.2 About the Authors 37

4.2.1 Epidemiologist 37

4.2.2 Reviewers 37

4.2.3 Global Director of Therapy Analysis and Epidemiology 38

4.2.4 Global Head and EVP of Healthcare Operations and Strategy 38

4.3 About GlobalData 39

4.4 Contact Us 39

4.5 Disclaimer 39


List Of Figure

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2016 and 2026 6

Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016 9

Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016 10

Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 11

Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 12

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 13

Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 20

Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 21

Figure 9: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016 22

Figure 10: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016 22

Figure 11: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016 24

Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016 25

Figure 13: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 26

Figure 14: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 27

Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016 29

Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016 30

Figure 17: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 31

Figure 18: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 32


List Of Table

1.1 List of Tables

Table 1: Relationship of Bleeding Severity with Clotting Factor Level. 7

Table 2: Comorbidities for Hemophilia 8

Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026. 19

Table 4: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 23

Table 5: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 28

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

EpiCast Report: Hemophilia-Epidemiology Forecast to 2026

Summary

Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (FVIII) in hemophilia A, or factor IX (FIX) in hemophilia B. Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease.

In the 7MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of hemophilia A and hemophilia B, from 51,627 diagnosed prevalent cases in 2016 to 52,566 diagnosed prevalent cases in 2026, with an Annual Growth Rate (AGR) of 0.18% during the forecast period. The US will have the highest number of diagnosed prevalent cases of hemophilia A and hemophilia B among the 7MM throughout the forecast period, while Spain will have the lowest.

GlobalData's epidemiologists forecast the epidemiological trend for hemophilia using the World Federation of Hemophilia (WFH) Annual Global Survey Report, which is considered the gold standard for hemophilia data. The World Health Organization (WHO) authenticates the WFH data for hemophilia and other bleeding disorders, and provides the most accurate data possible for hemophilia globally. The WFH Global Survey Report uses uniform data collection methods for each national member organization, allowing for a meaningful comparison of the diagnosed prevalent cases across the markets. A major strength of this analysis lays in the use of country-specific data and a uniform methodology across the markets to forecast the prevalent cases of hemophilia.

Scope

The Hemophilia EpiCast Report provides an overview of the risk factors and global trends of hemophilia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of diagnosed prevalent cases of hemophilia segmented by type (hemophilia A and hemophilia B), sex, and age (for all ages) in these seven markets.

The hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Hemophilia EpiCast report will allow you to

Develop business strategies by understanding the trends shaping and driving the global hemophilia market.

Quantify patient populations in the global hemophilia market to improve product design, pricing, and launch plans.

Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for hemophilia therapeutics in each of the markets covered.

Identify the percentage of hemophilia prevalent cases by type.

READ MORE

Scope

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 4

1.2 List of Figures 4

2 Hemophilia: Executive Summary 5

2.1 Related Reports 6

2.2 Upcoming Reports 6

3 Epidemiology 7

3.1 Disease Background 7

3.2 Risk Factors and Comorbidities 8

3.3 Global and Historical Trends 8

3.4 Forecast Methodology 10

3.4.1 Sources 10

3.4.2 Forecast Assumptions and Methods 13

3.4.3 Diagnosed Prevalent Cases 14

3.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 15

3.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitors 18

3.5 Epidemiological Forecast for Hemophilia A (2016-2026) 19

3.5.1 Diagnosed Prevalent Cases of Hemophilia A 19

3.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A 19

3.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A 20

3.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity 21

3.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors 22

3.6 Epidemiological Forecast for Hemophilia B (2016-2026) 23

3.6.1 Diagnosed Prevalent Cases of Hemophilia B 23

3.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia B 23

3.6.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia B 24

3.6.4 Diagnosed Prevalent Cases of Hemophilia B by Severity 25

3.6.5 Diagnosed Prevalent Cases of Hemophilia B with Inhibitors 27

3.7 Epidemiological Forecast for Hemophilia A and Hemophilia B (2016-2026) 27

3.7.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 27

3.7.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 28

3.7.3 Sex -Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 29

3.7.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 30

3.7.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 31

3.8 Discussion 32

3.8.1 Epidemiological Forecast Insight 32

3.8.2 Limitations of the Analysis 33

3.8.3 Strengths of the Analysis 33

4 Appendix 35

4.1 Bibliography 35

4.2 About the Authors 37

4.2.1 Epidemiologist 37

4.2.2 Reviewers 37

4.2.3 Global Director of Therapy Analysis and Epidemiology 38

4.2.4 Global Head and EVP of Healthcare Operations and Strategy 38

4.3 About GlobalData 39

4.4 Contact Us 39

4.5 Disclaimer 39


List Of Figure

1.2 List of Figures

Figure 1: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, 2016 and 2026 6

Figure 2: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia A (Cases per 100,000 Population), All Ages, 2016 9

Figure 3: 7MM, Age-Standardized Diagnosed Prevalence of Hemophilia B (Cases per 100,000 Population), All Ages, 2016 10

Figure 4: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B 11

Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity 12

Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors 13

Figure 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 20

Figure 8: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, 2016 21

Figure 9: 7MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, Both Sexes, All Ages, N, 2016 22

Figure 10: 7MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, Both Sexes, All Ages, N, 2016 22

Figure 11: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, 2016 24

Figure 12: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, 2016 25

Figure 13: 7MM, Diagnosed Prevalent Cases of Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 26

Figure 14: 7MM, Diagnosed Prevalent Cases of Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 27

Figure 15: 7MM, Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2016 29

Figure 16: 7MM, Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, All Ages, N, 2016 30

Figure 17: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, Both Sexes, All Ages, N, 2016 31

Figure 18: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, Both Sexes, All Ages, N, 2016 32


List Of Table

1.1 List of Tables

Table 1: Relationship of Bleeding Severity with Clotting Factor Level. 7

Table 2: Comorbidities for Hemophilia 8

Table 3: 7MM, Diagnosed Prevalent Cases of Hemophilia A, Both Sexes, All Ages, N, Selected Years 2016-2026. 19

Table 4: 7MM, Diagnosed Prevalent Cases of Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 23

Table 5: 7MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, Selected Years 2016-2026. 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com
chat_bubbleLet's Chat